Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“Just published – Open access
Pleased to share our standout new review published in The Lancet Group publication e-clinical medicine led by 3 amazing rising stars Jia Jenny Liu Niamh Coleman and Juliana Rodrigues Beal.
Title: Tumour‑agnostic immunotherapy: aligning biological rationale, biomarker precision, and real‑world implementation.
Authors: Jia Liu, Juliana Beal, Niamh Coleman, James Lynam, Vivek Subbiah
Tumour‑agnostic immunotherapy has reshaped precision oncology by showing that, in selected settings, treatment benefit can be driven by a shared biological state rather than anatomical origin.
The clearest example: MSI‑H/dMMR cancers, where durable responses span diverse malignancies.
Such a delight to work with and mentor this dream team their clarity, rigor, and vision shine through every section.”
You can also read:
PRINCE Trial: Biomarkers of ¹⁷⁷Lu-PSMA-617 Plus Pembrolizumab in mCRPC
